Anzeige
Mehr »
Login
Dienstag, 22.04.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Gold auf 4.000 USD? Goldman Sachs sagen Ja - und bei Forge sitzt der Ex-CFO von Newmont mit am Tisch
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJ4S | ISIN: DK0061123312 | Ticker-Symbol: 96X
Frankfurt
16.04.25
15:29 Uhr
3,170 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
FLUOGUIDE A/S Chart 1 Jahr
5-Tage-Chart
FLUOGUIDE A/S 5-Tage-Chart

Aktueller Chart FLUOGUIDE Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
FLUOGUIDE A/S-Investoren interessieren sich auch für diese Wertpapiere
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2024 ResultsSAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative...
► Artikel lesen
PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA GuidanceSAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative...
► Artikel lesen
GeneDx Announces Preliminary 2024 Financial ResultsSTAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for...
► Artikel lesen
GeneDx Reports Third Quarter 2024 Financial Results and Business HighlightsSTAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third...
► Artikel lesen
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 ResultsFRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary...
► Artikel lesen